Akèy › Sendwòm myelodisplastik › Minnesota
Etid klinik pou Sendwòm myelodisplastik nan Minnesota
13 etid pou Sendwòm myelodisplastik ap chèche patisipan nan sit nan Minnesota.
Vil nan Minnesota
Tèks ofisyèl etid la (Anglè)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- ak 5 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- ak 8 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT05320198The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
- Masonic Cancer Center, Minneapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT06594445Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
Ap rekriteFaz 2
Jiska laj 75 · Tout sèks · Mizajou Jul 6, 2026 · NCT05805605A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT03017820MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
Ap rekriteFaz 2
Laj 2 a 75 · Tout sèks · Mizajou Apr 16, 2026 · NCT07493538A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Mayo Clinic Comprehensive Cancer Center, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 13, 2026 · NCT05732103Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
Ap rekriteFaz 2
Jiska laj 65 · Tout sèks · Mizajou Jan 30, 2026 · NCT03579875SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Q702 for the Treatment of Patients With Hematologic Malignancies
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 10, 2025 · NCT06712810Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- University of Minnesota, Minneapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2025 · NCT06462365Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.